Neuroprotection devices market to grow ~7% by 2032 — here’s why investors should care

DelveInsight says the global neuroprotection devices market will expand at a CAGR of ~7% to 2032, led by cerebral embolic protection and North American demand.

What happened

On Sept. 24, 2025, DelveInsight released a market report forecasting steady growth in neuroprotection devices through 2032. The firm pegs the market to grow at a CAGR of ~7% between 2025 and 2032. The report names major makers — Medtronic, Boston Scientific Corporation, Abbott Laboratories and others — and highlights that the cerebral embolic protection devices category held the largest share in 2024. It also flags North America as the fastest-growing region.

The report notes recent product moves that matter to clinicians and investors. Contego Medical won FDA premarket approval (PMA) for its Neuroguard IEP® System in October 2024. InspireMD, Inc. secured CE Mark approval under the European Medical Device Regulation (MDR) in June 2025 for its CGuard® Prime EPS. Terumo launched its FDA-approved ROADSAVER™ Carotid Stent System in May 2025, designed to work with embolic protection tools.

Why it matters

Three simple forces are driving this growth: more patients, better hospitals, and smarter devices. The aging population and rising rates of stroke and carotid disease increase demand. Hospitals and specialized centers are adopting new tools as infrastructure improves. And device makers keep pushing incremental innovation — better filters, improved stents, and systems that reduce perioperative stroke risk.

For investors this matters for two reasons. First, the market is broadening. Cerebral embolic protection equipment and related systems are becoming routine in procedures once riskier. Second, regulatory wins and approvals are lowering barriers to adoption. PMA and MDR approvals speed clinic uptake and shrink commercial risk.

Outlook

The next few years should favor companies that combine clinical evidence with distribution. Expect steady, not explosive, revenue gains. North America will likely lead, driven by procedure volumes and reimbursement. Look for continued product launches, more clinical data, and incremental approvals that open new hospital accounts.

Risks remain. Reimbursement changes, mixed trial results, or a shift in procedural practice could slow uptake. But for now the market shows predictable growth and clear leaders.

Source: Company press release — link